| P/E (FY) | — | Sales (TTM) | $54.53B |
| Earnings (TTM) | $13.98B | ROE | 31.01% |
| Net Margin | 25.64% | ROIC | 43.62% |
| Debt / Equity | 0.01 | TD / EBITDA | — |
| EPS Growth 3Y | 31.14% | Sales Growth 3Y | 8.92% |
Novartis AG researches, develops, manufactures, markets, and sells pharmaceutical medicines in Switzerland and internationally. Its products include Entresto for chronic heart failure, Cosentyx for plaque psoriasis and related conditions, Kisqali (a CDK4/6 inhibitor), Promacta/Revolade for thrombocytopenia and aplastic anemia, the Tafinlar+Mekinist cancer combination, Jakavi for myelofibrosis and graft-versus-host disease, and Tasigna for chronic myeloid leukemia.
| Market Cap | — | Trading Days | 6589 |
| 52W High | 170.46 |
| 52W Low | 112.34 |
| % Off High | −6.82% |
| YTD | 18.71% | 1Y | 39.62% |
| 3Y | 77.48% | 5Y | 107.75% |
| 10Y | 206.90% | Since incept. (ann.) | 9.58% |
| Ann. Volatility (1Y) | 22.01% | Ann. Volatility (3Y) | 19.72% |
| Sharpe (1Y) | 1.69 | Sharpe (3Y) | 1.09 |
| Max Drawdown (1Y) | −12.65% | Max Drawdown (3Y) | −19.95% |
| Beta (3Y, vs SPY) | 0.10 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.14T | 52.7 |
| JNJ | JOHNSON & JOHNSON | $639.90B | 24.1 |
| ONC | BeOne Medicines Ltd. | $472.90B | 1722.2 |
| ABBV | AbbVie Inc. | $465.20B | 111.6 |
| MRK | Merck & Co., Inc. | $321.97B | 17.9 |
| ABT | ABBOTT LABORATORIES | $188.12B | 29.0 |
| PFE | PFIZER INC | $143.34B | 18.5 |
| BMY | BRISTOL MYERS SQUIBB CO | $128.85B | 18.2 |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $122.67B | 31.5 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $65.34B | 16.8 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $40.45B | 28.7 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.01B | 123.0 |